Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma

Popp, Ilinca; Bott, Stefan; Mix, Michael; Oehlke, Oliver; Schimek-Jasch, Tanja; Nieder, Carsten; Nestle, Ursula; Bock, Michael; Yuh, William T. C.; Meyer, Philipp T.; Weber, Wolfgang; Urbach, Horst; Mader, Irina; Grosu, Anca‐Ligia

doi:10.1016/j.radonc.2018.08.019

Cited by 27 publications

(19 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it remains unclear whether the cellular proliferation rate was associated with tumor progression or treatment-related tissue reactions such as inflammatory processes. On the other hand, several other studies reported contradictory results concerning the spatial congruency of amino acid uptake and ADC abnormalities [55,56,57]. Recently, Popp and co-workers [57] showed that tumor volumes in patients with recurrent glioblastoma delineated using ADC maps acquired at 1.5 T were frequently localized outside of areas with increased FET uptake.…”

Section: Amino Acid Pet and Dwimentioning

confidence: 99%

“…On the other hand, several other studies reported contradictory results concerning the spatial congruency of amino acid uptake and ADC abnormalities [55,56,57]. Recently, Popp and co-workers [57] showed that tumor volumes in patients with recurrent glioblastoma delineated using ADC maps acquired at 1.5 T were frequently localized outside of areas with increased FET uptake. Another study by Kinoshita [58] and colleagues reported that MET PET demonstrated a more robust and reliable estimation of cell density in gliomas compared to ADC maps acquired at 3 T. These controversial study results concerning the spatial congruency are most likely related to the fact that amino acid PET and DWI encode different biological properties [57,59] (Figure 3).…”

Section: Amino Acid Pet and Dwimentioning

confidence: 99%

See 1 more Smart Citation

Combined Amino Acid Positron Emission Tomography and Advanced Magnetic Resonance Imaging in Glioma Patients

Lohmann

Werner

Shah

et al. 2019

Cancers

View full text Add to dashboard Cite

Imaging techniques such as positron emission tomography (PET) and magnetic resonance imaging (MRI) provide valuable information about brain tumor patients. Particularly amino acid PET, advanced MRI techniques, and combinations thereof are of great interest for the non-invasive assessment of biological characteristics in patients with primary or secondary brain cancer. A methodological innovation that potentially advances research in patients with brain tumors is the increasing availability of hybrid PET/MRI systems, which enables the simultaneous acquisition of both imaging modalities. Furthermore, the advent of ultra-high field MRI scanners operating at magnetic field strengths of 7 T or more will allow further development of metabolic MR imaging at higher resolution. This review focuses on the combination of amino acid PET with MR spectroscopic imaging, perfusion- and diffusion-weighted imaging, as well as chemical exchange saturation transfer in patients with high-grade gliomas, especially glioblastomas.

show abstract

Section: Amino Acid Pet and Dwimentioning

confidence: 99%

Section: Amino Acid Pet and Dwimentioning

confidence: 99%

Combined Amino Acid Positron Emission Tomography and Advanced Magnetic Resonance Imaging in Glioma Patients

Lohmann

Werner

Shah

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…Molecular Imaging two that used FDOPA PET [42,43], three with MET PET [44][45][46], and two that used FET PET [36,47], showed mixed results. Overall, there were contradictory results as to whether aaPET uptake was congruent with DWI diffusion coefficient, but aaPET was overall superior for estimating tumor cell density and for differentiating tumor progression from treatment-related changes.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Amino Acid PET to Advanced and Emerging MRI Techniques for Neurooncology Imaging: A Systematic Review of the Recent Studies

2021

View full text Add to dashboard Cite

Introduction. Standard neuroimaging protocols for brain tumors have well-known limitations. The clinical use of additional modalities including amino acid PET (aaPET) and advanced MRI (aMRI) techniques (including DWI, PWI, and MRS) is emerging in response to the need for more accurate detection of brain tumors. In this systematic review of the past 2 years of the literature, we discuss the most recent studies that directly compare or combine aaPET and aMRI for brain tumor imaging. Methods. A PubMed search was conducted for human studies incorporating both aaPET and aMRI and published between July 2018 and August 2020. Results. A total of 22 studies were found in the study period. Recent studies of aaPET with DWI showed a superiority of MET, FET, FDOPA, and AMT PET for detecting tumor, predicting recurrence, diagnosing progression, and predicting survival. Combining modalities further improved performance. Comparisons of aaPET with PWI showed mixed results about spatial correlation. However, both modalities were able to detect high-grade tumors, identify tumor recurrence, differentiate recurrence from treatment effects, and predict survival. aaPET performed better on these measures than PWI, but when combined, they had the strongest results. Studies of aaPET with MRS demonstrated that both modalities have diagnostic potential but MET PET and FDOPA PET performed better than MRS. MRS suffered from some data quality issues that limited analysis in two studies, and, in one study that combined modalities, overall performance actually decreased. Four recent studies compared aaPET with emerging MRI approaches (such as CEST imaging, MR fingerprinting, and SISTINA), but the initial results remain inconclusive. Conclusions. aaPET outperformed the aMRI imaging techniques in most recent studies. DWI and PWI added meaningful complementary data, and the combination of aaPET with aMRI yielded the best results in most studies.

show abstract

“…Contouring recurrent high-grade glioma on the basis of gadolinium-enhanced T1-weighted gadolinium MRI alone guarantees a specificity of only 50% 44 . Other imaging modalities have been used to delineate the GTV, including MR-spectroscopy, perfusion-weighted imaging and diffusion weighted imaging 10 , 45 , 11C-methionine positron emission tomography (MET-PET) 46 , and18 F-dihydroxyphenylalanine (DOPA) PET 47 . In the majority of studies 12 , 17 , 48 – 50 , the authors delineate only contrast-enhancing lesion on T1-weighted images GTV, while the clinical target volume (CTV) is equal to the GTV.…”

Section: Discussionmentioning

confidence: 99%

Re-irradiation of recurrent glioblastoma using helical TomoTherapy with simultaneous integrated boost: preliminary considerations of treatment efficacy

Arpa

Parisi

Ghigi

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Although there is still no standard treatment for recurrent glioblastoma multiforme (rGBM), re-irradiation could be a therapeutic option. We retrospectively evaluated the efficacy and safety of re-irradiation using helical TomoTherapy (HT) with a simultaneous integrated boost (SIB) technique in patients with rGBM. 24 patients with rGBM underwent HT-SIB. A total dose of 20 Gy was prescribed to the Flair (fluid-attenuated inversion recovery) planning tumor volume (PTV) and 25 Gy to the PTV-boost (T1 MRI contrast enhanced area) in 5 daily fractions to the isodose of 67% (maximum dose within the PTV-boost was 37.5 Gy). Toxicity was evaluated by converting the 3D-dose distribution to the equivalent dose in 2 Gy fractions on a voxel-by-voxel basis. Median follow-up after re-irradiation was 27.8 months (range 1.6–88.5 months). Median progression-free survival (PFS) was 4 months (95% CI 2.0–7.9 months), while 6-month PFS was 41.7% (95% CI 22.2–60.1 months). Median overall survival following re-irradiation was 10.7 months (95% CI 7.4–16.1 months). There were no cases of re-operation due to early or late toxicity. Our preliminary results suggest that helical TomoTherapy with the proposed SIB technique is a safe and feasible treatment option for patients with rGBM, including those large disease volumes, reducing toxicity.

show abstract

Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma

Cited by 27 publications

References 30 publications

Combined Amino Acid Positron Emission Tomography and Advanced Magnetic Resonance Imaging in Glioma Patients

Combined Amino Acid Positron Emission Tomography and Advanced Magnetic Resonance Imaging in Glioma Patients

Comparison of Amino Acid PET to Advanced and Emerging MRI Techniques for Neurooncology Imaging: A Systematic Review of the Recent Studies

Re-irradiation of recurrent glioblastoma using helical TomoTherapy with simultaneous integrated boost: preliminary considerations of treatment efficacy

Contact Info

Product

Resources

About